SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Interim Management Statement

25 Jul 2018 07:00

RNS Number : 6360V
Victrex PLC
25 July 2018
 
 

 

 

 

25 July 2018

Victrex plc: Interim Management Statement

 'On track for a strong FY18'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its Interim Management Statement for the third quarter (Q3) covering the period 1 April to 30 June 2018.

Victrex has performed well since the end of the first half and cash generation has remained strong. Core business momentum has continued, with the majority of our markets in growth. Q3 saw a slightly lower contribution from the large Consumer Electronics order and with no volumes expected from this order in the fourth quarter, we will see a tougher Q4 comparative versus last year.

 

Medical revenue was in line with the prior year. Despite the challenging US Spine market, we still anticipate delivering meaningful revenue this year for our differentiated and innovative PEEK-OPTIMATM HA Enhanced product.

 

Overall, Q3 Group sales volume was up 14% to 1,161 tonnes (Q3 2017: 1,022 tonnes), with Group revenue up 10% to £84.0m (Q3 2017: £76.3m). Year to date Group sales volume of 3,417 tonnes is 19% up on the prior year (2017 YTD: 2,881 tonnes), with year to date Group revenue of £250.6m up 21% (2017 YTD: £207.3m).

Mega-programme progress

Victrex continues to focus on delivering further milestones in its growth pipeline and mega-programmes.

 

Following a commitment to deploy Magma's flexible oil & gas composite pipe by Tullow in West Africa, additional opportunities are under discussion, both with Tullow and other operators, in FY19. In Aerospace, construction of our US manufacturing facility, to support our TxV Aero Composites joint venture, is nearing completion, with prototype orders already in place. In Medical, following the agreement with Straumann Dental to enhance market access for our Juvora Dental product, we are in discussions for further customer agreements.

 

Currency

Currency remains in line with guidance for FY18, with approximately 90% of the FY18 currency benefit already seen in the first half, and a much lower benefit in the second half year. Looking ahead to 2019, over 50% of our currency hedges are in place. Although Sterling has slightly weakened since the end of our first half year, our guidance for FY19 remains similar, with an approximately £8m - £10m headwind to profits based on current rates and hedging in place, and reflecting some emerging raw material inflation.

 

Outlook

With continued momentum in our core business and milestones in our mega-programmes, we remain well positioned to continue driving growth as part of our Polymer & Parts strategy.

 

Although growth comparatives will be tougher in Q4, and we will see currency becoming a headwind, Victrex remains comfortable with full year expectations. Overall, we are on track to deliver a strong performance for FY18 as a whole.

 

 

Analyst & investor conference call

A conference call for analysts & investors will be held today, Wednesday 25 July at 08.00 BST.

Dial in details: +44 3333 000804 PIN: 96849285#

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Communications +44 (0) 7809 595831

Richard Armitage, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications, which contain our materials - from smart phones, aeroplanes and cars to oil and gas operations and medical devices. With over 35 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTEASXLADDPEFF
Date   Source Headline
20th May 20147:00 amRNSHalf Yearly Report
19th May 201411:57 amRNSDirector/PDMR Shareholding
30th Apr 20143:16 pmRNSTotal Voting Rights
17th Apr 20142:01 pmRNSDirector/PDMR Shareholding
10th Apr 20142:49 pmRNSHolding(s) in Company
8th Apr 20147:00 amRNSTrading Statement
3rd Apr 20141:33 pmRNSHolding(s) in Company
31st Mar 20144:25 pmRNSTotal Voting Rights
18th Mar 20144:29 pmRNSDirector/PDMR Shareholding
12th Mar 20143:08 pmRNSHolding(s) in Company
3rd Mar 201410:18 amRNSHolding(s) in Company
28th Feb 20142:00 pmRNSTotal Voting Rights
19th Feb 20145:04 pmRNSDirector/PDMR Shareholding
18th Feb 201412:01 pmRNSDirector/PDMR Shareholding
4th Feb 20142:17 pmRNSResult of AGM
4th Feb 20147:00 amRNSAGM and Q1 Interim Management Statement
31st Jan 20143:30 pmRNSDirectorate Change
31st Jan 20149:00 amRNSTotal Voting Rights
17th Jan 201410:07 amRNSDirector/PDMR Shareholding
15th Jan 20144:42 pmRNSHolding(s) in Company
14th Jan 20143:06 pmRNSDirector/PDMR Shareholding
2nd Jan 201411:37 amRNSAnnual Financial Report
31st Dec 20137:00 amRNSTotal Voting Rights
17th Dec 20135:17 pmRNSDirector/PDMR Shareholding
17th Dec 20134:47 pmRNSDirector/PDMR Shareholding
17th Dec 201311:36 amRNSDirector/PDMR Shareholding
13th Dec 20133:14 pmRNSHolding(s) in Company
10th Dec 20137:00 amRNSFinal Results
2nd Dec 20134:19 pmRNSBlocklisting Interim Review
29th Nov 20138:39 amRNSTotal Voting Rights
19th Nov 20132:16 pmRNSDirector/PDMR Shareholding
13th Nov 20133:33 pmRNSDirector Declaration
7th Nov 20137:00 amRNSDirectorate Change
31st Oct 20132:47 pmRNSTotal Voting Rights
25th Oct 201311:46 amRNSHolding(s) in Company
17th Oct 20132:31 pmRNSDirector/PDMR Shareholding
14th Oct 20133:51 pmRNSHolding(s) in Company
14th Oct 20133:48 pmRNSHolding(s) in Company
10th Oct 20137:00 amRNSInvestor Day
8th Oct 20137:00 amRNSTrading Statement
1st Oct 20134:31 pmRNSHolding(s) in Company
30th Sep 20132:56 pmRNSTotal Voting Rights
17th Sep 20133:35 pmRNSDirector/PDMR Shareholding
11th Sep 20133:45 pmRNSHolding(s) in Company
4th Sep 20138:42 amRNSDirector Declaration
30th Aug 20131:53 pmRNSHolding(s) in Company
30th Aug 20138:33 amRNSTotal Voting Rights
19th Aug 20134:07 pmRNSDirector/PDMR Shareholding
2nd Aug 20138:48 amRNSHolding(s) in Company
29th Jul 20137:56 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.